US Approves Etcamah Combination for First-Line Advanced HR-Positive Breast Cancer
The US FDA has approved AstraZeneca's Etcamah in combination with a CDK4/6 inhibitor for specific cases of advanced HR-positive breast cancer. This approval targets patients with an ESR1 mutation detected during prior therapy.
AstraZeneca's Etcamah (camizestrant) has received US Food and Drug Administration (FDA) approval for use in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor. The treatment is indicated for adult patients with hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer who have an ESR1 mutation detected during aromatase inhibitor (AI) and CDK4/6 inhibitor therapy.
The approval stems from results of the SERENA-6 Phase III trial, which demonstrated that the Etcamah combination reduced the risk of disease progression or death by 56% compared to standard of care. This represents a significant advancement for patients whose cancer develops resistance to existing treatments.
This new approach allows for earlier intervention by detecting ESR1 mutations, which are a key driver of endocrine resistance. Identifying these mutations via a blood test enables a switch in therapy before overt disease progression, potentially improving patient outcomes and quality of life.
Breast cancer is the most common cancer among women in the US. The approval of Etcamah in combination therapy offers a vital new option for a patient population with historically limited treatment alternatives once resistance emerges.